Cisd2 Protects the Liver from Oxidative Stress and Ameliorates Western Diet-Induced Nonalcoholic Fatty Liver Disease.
Study Goal
The researchers sought to determine the role of Cisd2 in modulating Western diet-induced NAFLD and NASH severity and explore its potential as a therapeutic target.
Results Summary
The study found that Cisd2 dosage influences NAFLD progression, with haploinsufficiency worsening liver damage and increased expression protecting against oxidative stress and mitochondrial DNA damage. Transcriptomic analysis linked Western diet consumption to inflammation, lipid metabolism disruption, and DNA replication/repair issues.
Population
Mice fed a Western diet.
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
Cisd2 haploinsufficiency | increase | NAFLD development | mice fed a Western diet | - | accelerates | #1 |
Cisd2 haploinsufficiency | increase | NASH | mice fed a Western diet | - | exacerbates progression toward | #2 |
enhanced Cisd2 copy number | decrease | liver pathogenesis | mice fed a Western diet | - | attenuates | #3 |
Western diet | increase | inflammation, lipid metabolism, and DNA replication/repair | mice | - | reveals that the major alterations affecting biological processes are related to | #4 |
Western diet | increase | Nrf2-mediated oxidative stress, cholesterol biosynthesis, and fatty acid metabolism | mice | - | the most significant changes involve | #5 |
increased Cisd2 expression | decrease | oxidative stress | - | - | protects the liver from | #6 |
increased Cisd2 expression | decrease | mitochondrial DNA deletions | - | - | reduces the occurrence of | #7 |
Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic steatohepatitis (NASH), are the most common chronic liver diseases worldwide. However, drugs to treat NAFLD and NASH are an unmet clinical need. This study sought to provide evidence that Cisd2 is a molecular target for the development of treatments targeting NAFLD and NASH. Several discoveries are pinpointed. The first is that Cisd2 dosage modulates the severity of Western diet-induced (WD-induced) NAFLD. Specifically, Cisd2 haploinsufficiency accelerates NAFLD development and exacerbates progression toward NASH. Conversely, an enhanced Cisd2 copy number attenuates liver pathogenesis. Secondly, when a WD is fed to mice, transcriptomic analysis reveals that the major alterations affecting biological processes are related to inflammation, lipid metabolism, and DNA replication/repair. Thirdly, among these differentially expressed genes, the most significant changes involve Nrf2-mediated oxidative stress, cholesterol biosynthesis, and fatty acid metabolism. Finally, increased Cisd2 expression protects the liver from oxidative stress and reduces the occurrence of mitochondrial DNA deletions. Taken together, our mouse model reveals that Cisd2 plays a crucial role in protecting the liver from WD-induced damages. The development of therapeutic agents that effectively enhance Cisd2 expression is one potential approach to the treatment of WD-induced fatty liver diseases.